Cardiovascular Science News from the University of Rochester Medical Center
The drug ranolazine, approved to treat chest pain, is being tested as a potential treatment for ventricular arrhythmias. The University of Rochester Medical Center is leading the new nationwide clinical trial, funded with a $10.5 million grant from the National Institutes of Health. It’s the first major study testing a new concept – blocking late sodium currents that govern key components of the electrical activity in the heart – to combat these deadly arrhythmias.
Can the body’s natural response to emotions such as fear and rage be used to combat heart failure? Scientists have found that two experimental compounds have the potential to restore pumping strength to failing hearts in part by harnessing the fight-or-flight response that makes hearts beat stronger. The work was published in Circulation Research.
Scientists from Rochester presented several findings at the Scientific Sessions of the American Heart Association in Chicago. Physicians discussed new results from the groundbreaking MADIT-CRT trial. Other presentations focused on a potential new target to stop atherosclerosis, on the activity of Notch in the body, and the role of thioredoxin-interacting protein and thioredoxin1 in cardiac disease.
AstraZeneca has purchased a one-year membership to gain access to an international repository of data designed to aid industry and academic researchers developing new technologies to improve cardiac safety. The database, called the Telemetric and Holter ECG Warehouse, helps researchers better evaluate how drugs affect the heart.